We caught up with Prof Joachim Ehrlich (Head of Cardiology and Electrophysiology, St Josefs-Hospital, Wiesbaden, Germany) on the recent studies in the use of pulmonary vein isolation in patients with atrial fibrillation and heart failure and the advantages of cryoballoon ablation compared with radiofrequency ablation. He also gave us an overview of their recent cohort study and its findings.
- What have recent studies taught us about the utility of pulmonary vein isolation in patients with atrial fibrillation and heart failure? (0.18)
- What are the advantages of cryoballoon ablation compared with radiofrequency ablation in the treatment of atrial fibrillation? (2.15)
- Could you give us a brief overview of your cohort study and its findings? (3.12)
- What are the limitations of cryoballoon ablation in this patient population? (4.26)
- What will be the impact of your findings on clinical practice? (5.06)
Speaker’s disclosures: Professor Joachim Ehrlich has nothing to declare in relation to this video interview.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Joachim Ehrlich, September 2020.
Share this Video
Related Videos In Heart Failure
Justin Ezekowitz, ACC 2022: SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
The SODIUM-HF trial tested whether or not a reduction in dietary sodium reduces the incidence of heart failure. touchCARDIO speaks with Prof. Justin Ezekowitz (University of Alberta, Edmonton, Canada) to discuss his presentation on the SODIUM-HF study on the effect of sodium restriction on mortality and morbidity in patients with heart failure. The presentation entitled […]
Mikhail Kosiborod, ACC 2022: Results From the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure
The EMPULSE trial showed the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure. touchCARDIO speaks with Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO) to discuss his presentation on the EMPULSE trial and the impact of SGLT-2 inhibitors and where they […]
Mark Loeb, ACC 2022: IVVE: Randomized Controlled Trial of Influenza Vaccine in Patients with Heart Failure to Reduce Adverse Vascular Events
The IVVE study is a randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events. It was delightful to speak with Prof Mark Loeb (McMaster University, Hamilton, Canada) about his presentation at the American College of Cardiology Annual Meeting 2022. Questions: What is known about the effects of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!